Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Goff Corp. (GOFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.4930-0.0120 (-2.38%)
At close: 03:56PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5050
Open0.4900
BidN/A x N/A
AskN/A x N/A
Day's Range0.4444 - 0.5100
52 Week Range0.0330 - 0.7600
Volume316,749
Avg. Volume605,501
Market Cap112.527M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GOFF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GOFF CORP
    Analyst Report: The Procter & Gamble CompanySince its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, generating more than $75 billion in annual sales. It operates with a lineup of leading brands, including 21 that generate more than $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. P&G sold its last remaining food brand, Pringles, to Kellogg in calendar 2012. Sales outside its home turf represent around 55% of the firm's consolidated total, with around one third coming from emerging markets.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    NextCure and Collaborators Publish Preclinical Data on Novel Immunomedicine NC410

    BELTSVILLE, Md., June 21, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal eLife establishing NC410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. NC410, curr

Advertisement
Advertisement